ArticleJournal of thoracic disease2019
A systematic review and meta-analysis of stereotactic body radiation therapy for colorectal pulmonary metastases.
Article in Journal of thoracic disease, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 4 syntheses or guidelines pooled it, 52 citations in OpenAlex.
- Isolated para-aortic lymph node recurrence from colorectal cancer treated by radiotherapy: a systematic review and meta-analysis.Scientific reports · 2026Pooled it
- Stereotactic body radiation therapy and thermal ablation for treatment of patients with pulmonary metastases: a systematic literature review and meta-analysis.BMC pulmonary medicine · 2025Pooled it
- A Systematic Review and Meta-analysis of Patient Survival and Disease Recurrence Following Percutaneous Ablation of Pulmonary Metastasis.Cardiovascular and interventional radiology · 2022Pooled it
- Tumor Control and Overall Survival after Stereotactic Body Radiotherapy for Pulmonary Oligometastases from Colorectal Cancer: A Meta-Analysis.Cancer research and treatment · 2020Pooled it
- Metastasectomy versus stereotactic body radiotherapy for lung metastases: a systematic review and meta-analysis of reconstructed time-to-event data on overall and progression-free survival.Journal of thoracic disease · 2026Article
- Article
- Percutaneous Cryoablation Under Local Anesthesia for Pulmonary Metastases From Colorectal Cancer: Long-Term Outcomes From a Single-Institution Retrospective Cohort.Cancer reports (Hoboken, N.J.) · 2026Article
- Emerging Applications of Stereotactic Ablative Radiotherapy in Oligometastatic Colorectal Cancer.International journal of molecular sciences · 2025Review
- Prognostic factors and risk stratification for survival in oligometastatic colorectal cancer treated with stereotactic body radiotherapy.Radiation oncology journal · 2025Article
- Lung metastases.Nature reviews. Disease primers · 2025Review
- Cryoablation for treatment of peripheral lung metastases from colorectal cancer: a bicenter retrospective study.European radiology · 2025Article
- Ablative Techniques for Lung Metastases: Patient Selection and Outcomes Following Treatment with Stereotactic Radiotherapy or Radiofrequency Ablation.Current oncology (Toronto, Ont.) · 2025Article
- Effects of maximum dose on local control after stereotactic body radiotherapy for oligometastatic tumors of colorectal cancer.PloS one · 2025Article
- Evaluating the efficacy of stereotactic radiotherapy for metastatic colorectal cancer: A retrospective review of clinical outcomes.Journal of radiosurgery and SBRT · 2025Article
- A retrospective study comparing the efficacy of microwave ablation and stereotactic body radiotherapy in colorectal cancer lung metastases.Oncology letters · 2024Article
- Article
- CT-guided Percutaneous Microwave Ablation Combined with Local Radiotherapy or Chemotherapy of Malignant Pulmonary Tumors.Current radiopharmaceuticals · 2024Article
- Stereotactic body radiation therapy for lung metastases from colorectal cancer: outcomes and prognostic factors in a series of 109 patients.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2024Article
- Effect of histology on stereotactic body radiotherapy for non-small cell lung cancer oligometastatic pulmonary lesions.Translational lung cancer research · 2023Article
- Stereotactic body proton therapy for non-small cell lung cancer: Clinical indications and recommendations.Journal of radiosurgery and SBRT · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 2 countries.
Funding
Abstract
backgroundThere is growing evidence to support the hypothesis that radical treatment of pulmonary oligometastatic disease with stereotactic body radiation therapy (SBRT) can improve oncological outcomes. However, some reports suggest colorectal cancer (CRC) pulmonary metastases are associated with radioresistance. The present systematic review aimed to assess the local control (LC), overall survival (OS), and progression-free survival (PFS) of patients with CRC pulmonary metastases treated by SBRT. Secondary outcomes included assessment of peri-procedural complications and identification of prognostic factors on LC.
methodsElectronic databases were systematically searched from their dates of inception using predefined criteria. Summative statistical analysis was performed for patients with CRC pulmonary metastases, and comparative meta-analysis was performed for patients with CRC versus non-CRC pulmonary metastases.
resultsUsing predefined criteria, 18 relevant studies were identified from the existing literature. LC for CRC pulmonary metastases treated by SBRT at 1-, 2-, and 3-year were estimated to be 81%, 66%, and 60%, respectively. OS and PFS at 3-year were 52% and 13%, respectively. Patients with CRC pulmonary metastases were associated with significantly lower LC compared to non-CRC pulmonary metastases [HR, 2.93; 95% confidence interval (CI), 1.93-4.45; P<0.00001], but higher OS (HR, 0.61; 95% CI, 0.45-0.82; P=0.001). There were no reported periprocedural mortalities and low incidences of periprocedural morbidities.
conclusionsThese findings may have implications for patient and treatment selection, dose fractionation, and support the hypothesis that CRC pulmonary metastases may require higher biological effective doses while respecting normal tissue constraints when treated with SBRT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.